Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
life sciences
national
13
×
national blog main
national top stories
biotech
clinical trials
san francisco top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
eli lilly
gene therapy
novartis
amgen
drugs
genentech
medical device
abbvie
allergan
biogen
What
fda
13
×
drug
new
bio
roundup
approved
drugs
class
medicine
medicines
migraine
news
patients
therapy
won
approval
cancer
companies
gene
nod
oral
treatment
activity
adults
ahead
allergan
amgen
approvals
aren’t
arguments
asco
atrophy
august
big
biogen
biotech
branded
busy
candidates
cash
Language
unset
Current search:
national
×
fda
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
FDA Official: New “Playbook” Needed for CMC Reviews of Gene Therapy Products
@xconomy.com
3 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
4 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines